Rapid De-escalation of Anti-MRSA Therapy Guided by S. Aureus Nares Screening in Case of Pneumonia
Key facts
- Who runs it
- University of Bari Aldo Moro
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 76 people, planned
- Started
- 6 May 2024
- Planned end
- 30 Jun 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- MRSA nasal swab based de-escalation
- Record updated
- 30 May 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Subjects 18 years or older
- Patients hospitalized at the Azienda Consorziale Policlinico di Bari
- Clinical diagnosis of CAP/HAP/VAP
- Commitment by the prescribing physician to set an anti-MRSA antibiotic therapy in empirical
- Enrollement within 48h from the beginning of the empirical anti-MRSA therapy
Who cannot take part
- Enrollment after 48 hours from the beginning of the empirical anti-MRSA therapy
- Chronic airway infection (eg cystic fibrosis)
- Suspect of extrapulmonary infection by MRSA
- Febrile neutropenia or severe immunodeficiency
- Refusal by the patient or legal guardian
- Refusal by the physician in charge of the patient to perform antibiotic de-escalation based on the result of the nasal swab
This trial is currently available in Italy.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The current IDSA/ATS guidelines recommend Linezolid and Vancomycin for MRSA coverage in hospitalized patients with pneumonia, which is common clinical practice in Italy. However, a nasal PCR-assay for MRSA has a high negative predictive value and can facilitate rapid antibiotic de-escalation, thereby avoiding unnecessary anti-MRSA treatments. The indiscriminate use of these drugs has contributed to the emergence of resistant S. aureus strains and has led to significant adverse effects, without providing any survival benefits. Additionally, it has increased hospital stays and associated costs. The proposed study aims to use this diagnostic tool to shorten empirical anti-MRSA treatment duration in pneumonia patients, focusing on reducing antimicrobial therapy days while measuring in-hospital mortality, length of stay and adverse drug event incidence.
The 2 groups in the trial
- InterventionTreatment being tested
Patients included into the intervention arm will undergo a nasal swab for MRSA and empirical anti-MRSA therapy will be discontinued f the nasal swab result is negative.
Treatment: MRSA nasal swab based de-escalation
- ControlNo study treatment, for comparison
Patients randomized into the control arm will continue pneumonia treatment as per standard of care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Rapid De-escalation of Anti-MRSA Therapy Guided by S. Aureus Nares Screening in Case of Pneumonia (SNAP Study)
- Publications
- Record updated
- 30 May 2025